TITLE

Duloxetine in the treatment of major depressive disorder: an open-label study

AUTHOR(S)
Hudson, James I.; Perahia, David G.; Gilaberte, Inmaculada; Fujun Wang; Watkin, John G.; Detke, Michael J.
PUB. DATE
January 2007
SOURCE
BMC Psychiatry;2007, Vol. 7, p43
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Major depressive disorder (MDD) is a chronic and highly disabling condition. Existing pharmacotherapies produce full remission in only 30% to 40% of treated patients. Antidepressants exhibiting dual reuptake inhibition of both serotonin (5-HT) and norepinephrine (NE) may achieve higher rates of remission compared with those acting upon a single neurotransmitter. In this study, the safety and efficacy of duloxetine, a potent dual reuptake inhibitor of 5-HT and NE, were examined. Methods: Patients (N = 533) meeting DSM-IV criteria for MDD received open-label duloxetine (60 mg once a day [QD]) for 12 weeks during the initial phase of a relapse prevention trial. Patients were required to have a 17-item Hamilton Rating Scale for Depression (HAMD17) total score ≥18 and a Clinical Global Impression of Severity (CGI-S) score ≥4 at baseline. Efficacy measures included the HAMD17 total score, HAMD17 subscales, the CGI-S, the Patient Global Impression of Improvement (PGI-I) scale, Visual Analog Scales (VAS) for pain, and the Symptom Questionnaire, Somatic Subscale (SQ-SS). Quality of life was assessed using the Sheehan Disability Scale (SDS) and the Quality of Life in Depression Scale (QLDS). Safety was evaluated by recording spontaneously-reported treatment-emergent adverse events, changes in vital signs and laboratory analytes, and the Patient Global Impression of Sexual Function (PGI-SF) scale. Results: The rate of discontinuation due to adverse events was 11.3%. Treatment-emergent adverse events reported by ≥10% duloxetine-treated patients were nausea, headache, dry mouth, somnolence, insomnia, and dizziness. Following 12 weeks of open-label duloxetine therapy, significant improvements were observed in all assessed efficacy and quality of life measures. In assessments of depression severity (HAMD17, CGI-S) the magnitude of symptom improvement continued to increase at each study visit, while for painful physical symptoms the onset of improvement was rapid and reached a maximum after 2 to 3 weeks of treatment. Conclusion: In this open-label phase of a relapse prevention study, duloxetine (60 mg QD) was shown to be safe and effective in the treatment of MDD.
ACCESSION #
29962959

 

Related Articles

  • Still Struggling: Characteristics of Youth With OCD Who are Partial Responders to Medication Treatment. Freeman, J.; Sapyta, J.; Garcia, A.; Fitzgerald, D.; Khanna, M.; Choate-Summers, M.; Moore, P.; Chrisman, A.; Haff, N.; Naeem, A.; March, J.; Franklin, M. // Child Psychiatry & Human Development;Aug2011, Vol. 42 Issue 4, p424 

    The primary aim of this paper is to examine the characteristics of a large sample of youth with OCD who are partial responders (i.e., still have clinically significant symptoms) to serotonin reuptake inhibitor (SRI) medication. The sample will be described with regard to: demographics, treatment...

  • Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. Hotopf, Matthew; Hardy, Rebecca; Lewis, Glyn; Hotopf, M; Hardy, R; Lewis, G // British Journal of Psychiatry;Feb97, Vol. 170, p120 

    Background: Previous meta-analyses suggest that individuals treated with serotonin-specific reuptake inhibitors (SSRIs) in randomised controlled trials (RCTs) are less likely to discontinue treatment than those on tricyclic antidepressants. This metaanalysis investigates whether...

  • sertraline.  // Davis's Drug Guide for Nurses, 10th edition;2007, p1070 

    The article presents information on sertraline, a selective serotonin reuptake inhibitor used in the management of depression, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, social anxiety disorder and premenstrual dysphoric disorder. Some of its side effects...

  • Simultaneous analyses of the neurochemical and behavioral effects of the norepinephrine reuptake inhibitor reboxetine in a rat model of antidepressant action. Page, Michelle E.; Brown, Kevin; Lucki, Irwin // Psychopharmacology;2003, Vol. 165 Issue 2, p194 

    Investigates the simultaneous neurochemical and behavioral effects of the norepinephrine reuptake inhibitor reboxetine in a rat model of antidepressant action. Noradrenergic responses; Neurotransmitter levels and behavior; Precipitation of depressive symptomatology.

  • Safety of 5-HT reuptake inhibitors. Harrison, Debbie; Harrison, D // British Journal of Psychiatry;Jun92, Vol. 160, p866 

    A letter to the editor is presented in response to a letter about the safety of 5-HT reuptake inhibitors.

  • In this issue.  // Journal of Palliative Medicine;Feb2006, Vol. 9 Issue 1, p1 

    The article discusses various reports published within the issue, including one about dulexitine, a dual reuptake inhibitor of both serotonin and norepinephrine for the neuropathic pain of diabetes and the other about the reduction of the potency of prescribed opioid analgesia when patients are...

  • Crane remote controller.  // Manufacturers' Monthly;Sep2009, p51 

    The article evaluates the Remotus MB-28 transmitter from Akerstroms.

  • GABA Uptake Inhibitors. Design, Molecular Pharmacology and Therapeutic Aspects. Krogsgaard-Larsen, Povl; Frolund, Bente; Frydenvang, Karla // Current Pharmaceutical Design;Aug2000, Vol. 6 Issue 12, p1193 

    In the mid seventies a drug design programme using the Amanita muscaria constituent muscimol (7) as a lead structure, led to the design of guvacine (23) and (R)-nipecotic acid (24) as specific GABA uptake inhibitors and the isomeric compounds isoguvacine (10) and isonipecotic acid (11) as...

  • Behavioral stimulation without alteration of β and 5-HT receptors and adenylate cyclase activity in rat brain after chronic sertraline administration. Tadokoro, C.; Kiuchi, Y.; Yamazaki, Y.; Nara, K.; Oguchi, K.; Kamijima, K. // Psychopharmacology;1997, Vol. 130 Issue 2, p124 

    Abstract Effects of chronic treatment with selective 5-HT reuptake inhibitors (SSRIs) on the monoaminergic functions have not been much investigated in compared with tricyclic antidepressants. Therefore, we compared the effects of 3-week treatment with sertraline, a potent SSRI, to those of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics